Bavarian Nordic A/S (BVNRY)
USD 7.36
(-2.26%)
USD 7.36
(-2.26%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 4.01 Billion DKK | -23.43% |
| 2022 | 5.24 Billion DKK | 11.17% |
| 2021 | 4.71 Billion DKK | 21.99% |
| 2020 | 3.86 Billion DKK | -25.41% |
| 2019 | 5.18 Billion DKK | 488.61% |
| 2018 | 880.3 Million DKK | 36.19% |
| 2017 | 646.37 Million DKK | -19.85% |
| 2016 | 806.46 Million DKK | 24.69% |
| 2015 | 646.78 Million DKK | 1.83% |
| 2014 | 635.17 Million DKK | 33.46% |
| 2013 | 475.91 Million DKK | -11.79% |
| 2012 | 539.5 Million DKK | -29.84% |
| 2011 | 768.98 Million DKK | 17.1% |
| 2010 | 656.69 Million DKK | 15.84% |
| 2009 | 566.89 Million DKK | -16.53% |
| 2008 | 679.13 Million DKK | 32.03% |
| 2007 | 514.38 Million DKK | 95.57% |
| 2006 | 263.02 Million DKK | -11.87% |
| 2005 | 298.46 Million DKK | 4.1% |
| 2004 | 286.71 Million DKK | 248.93% |
| 2003 | 82.16 Million DKK | -32.24% |
| 2002 | 121.26 Million DKK | 583.9% |
| 2001 | 17.73 Million DKK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 3.44 Billion DKK | -14.12% |
| 2024 Q2 | 3.83 Billion DKK | 11.35% |
| 2023 FY | 4.01 Billion DKK | -23.43% |
| 2023 Q3 | 4.06 Billion DKK | -23.44% |
| 2023 Q2 | 5.3 Billion DKK | 30.73% |
| 2023 Q1 | 4.05 Billion DKK | -22.54% |
| 2023 Q4 | 4.01 Billion DKK | -1.23% |
| 2022 Q1 | 4.86 Billion DKK | 3.22% |
| 2022 FY | 5.24 Billion DKK | 11.17% |
| 2022 Q2 | 5.14 Billion DKK | 5.82% |
| 2022 Q4 | 5.24 Billion DKK | -1.8% |
| 2022 Q3 | 5.33 Billion DKK | 3.65% |
| 2021 Q4 | 4.71 Billion DKK | 8.46% |
| 2021 FY | 4.71 Billion DKK | 21.99% |
| 2021 Q1 | 3.82 Billion DKK | -0.96% |
| 2021 Q2 | 4.21 Billion DKK | 10.24% |
| 2021 Q3 | 4.34 Billion DKK | 3.01% |
| 2020 Q4 | 3.86 Billion DKK | -7.7% |
| 2020 Q1 | 3.89 Billion DKK | -24.84% |
| 2020 FY | 3.86 Billion DKK | -25.41% |
| 2020 Q2 | 3.99 Billion DKK | 2.49% |
| 2020 Q3 | 4.18 Billion DKK | 4.9% |
| 2019 Q3 | 671.11 Million DKK | -2.09% |
| 2019 FY | 5.18 Billion DKK | 488.61% |
| 2019 Q1 | 674.66 Million DKK | -23.36% |
| 2019 Q2 | 685.45 Million DKK | 1.6% |
| 2019 Q4 | 5.18 Billion DKK | 672.09% |
| 2018 FY | 880.3 Million DKK | 36.19% |
| 2018 Q4 | 880.3 Million DKK | 6.73% |
| 2018 Q3 | 824.77 Million DKK | -8.94% |
| 2018 Q2 | 905.73 Million DKK | 29.99% |
| 2018 Q1 | 696.76 Million DKK | 7.8% |
| 2017 Q3 | 278.85 Million DKK | -70.51% |
| 2017 Q2 | 945.59 Million DKK | 12.33% |
| 2017 Q1 | 841.79 Million DKK | 4.38% |
| 2017 Q4 | 646.37 Million DKK | 131.8% |
| 2017 FY | 646.37 Million DKK | -19.85% |
| 2016 Q2 | 677.23 Million DKK | 4.16% |
| 2016 Q1 | 650.17 Million DKK | 0.52% |
| 2016 FY | 806.46 Million DKK | 24.69% |
| 2016 Q4 | 806.46 Million DKK | 20.67% |
| 2016 Q3 | 668.32 Million DKK | -1.32% |
| 2015 Q1 | 1.19 Billion DKK | 88.14% |
| 2015 Q3 | 836.47 Million DKK | -4.05% |
| 2015 Q4 | 646.78 Million DKK | -22.68% |
| 2015 FY | 646.78 Million DKK | 1.83% |
| 2015 Q2 | 871.8 Million DKK | -27.05% |
| 2014 FY | 635.17 Million DKK | 33.46% |
| 2014 Q2 | 330.2 Million DKK | -6.64% |
| 2014 Q1 | 353.7 Million DKK | -25.68% |
| 2014 Q4 | 635.17 Million DKK | 66.15% |
| 2014 Q3 | 382.3 Million DKK | 15.78% |
| 2013 Q4 | 475.91 Million DKK | 3.96% |
| 2013 Q3 | 457.8 Million DKK | -13.87% |
| 2013 Q2 | 531.5 Million DKK | 24.27% |
| 2013 Q1 | 427.7 Million DKK | -20.72% |
| 2013 FY | 475.91 Million DKK | -11.79% |
| 2012 FY | 539.5 Million DKK | -29.84% |
| 2012 Q3 | 591.7 Million DKK | -11.63% |
| 2012 Q2 | 669.6 Million DKK | -3.08% |
| 2012 Q1 | 690.9 Million DKK | -10.15% |
| 2012 Q4 | 539.5 Million DKK | -8.82% |
| 2011 Q3 | 646.2 Million DKK | -2.68% |
| 2011 Q4 | 768.98 Million DKK | 19.0% |
| 2011 FY | 768.98 Million DKK | 17.1% |
| 2011 Q2 | 664 Million DKK | 2.06% |
| 2011 Q1 | 650.6 Million DKK | -0.93% |
| 2010 Q3 | 675.3 Million DKK | -8.52% |
| 2010 Q4 | 656.69 Million DKK | -2.76% |
| 2010 FY | 656.69 Million DKK | 15.84% |
| 2010 Q1 | 542.7 Million DKK | -4.27% |
| 2010 Q2 | 738.2 Million DKK | 36.02% |
| 2009 Q4 | 566.89 Million DKK | 0.0% |
| 2009 FY | 566.89 Million DKK | -16.53% |
| 2008 FY | 679.13 Million DKK | 32.03% |
| 2007 FY | 514.38 Million DKK | 95.57% |
| 2006 FY | 263.02 Million DKK | -11.87% |
| 2005 FY | 298.46 Million DKK | 4.1% |
| 2004 FY | 286.71 Million DKK | 248.93% |
| 2003 FY | 82.16 Million DKK | -32.24% |
| 2002 FY | 121.26 Million DKK | 583.9% |
| 2001 FY | 17.73 Million DKK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -14629291.609% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -7884.404% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -6700.552% |
| Neon Bloom, Inc. | 1.22 Million USD | -327190.691% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -496105.585% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -8978960.766% |
| Qrons Inc. | 1.48 Million USD | -269480.571% |
| Regen BioPharma, Inc. | 5.45 Million USD | -73435.423% |
| BioStem Technologies, Inc. | 15.9 Million USD | -25133.354% |
| CSL Limited | 18.62 Billion USD | 78.448% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -5256.755% |
| Skye Bioscience, Inc. | 14.07 Million USD | -28419.156% |
| Rebus Holdings, Inc. | 5.24 Million USD | -76460.111% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -1995405.579% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -42297.153% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -5437.775% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -7428.902% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -41783.446% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -951889.003% |
| SQZ Biotechnologies Company | 50.03 Million USD | -7920.306% |
| Intellipharmaceutics International Inc. | 12 Million USD | -33319.593% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -104102.524% |
| Mesoblast Limited | 188.44 Million USD | -2029.687% |
| Marizyme, Inc. | 26.67 Million USD | -14944.701% |
| Genus plc | 485 Million USD | -727.481% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -68589.737% |
| Pharming Group N.V. | 244.07 Million USD | -1544.295% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -199552.809% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -159389.582% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -105512.658% |
| ContraFect Corporation | 32.53 Million USD | -12236.79% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -202457.149% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -104749.793% |
| IMV Inc. | 37.93 Million USD | -10479.977% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -33973.82% |
| MultiCell Technologies, Inc. | 1617.67 USD | -248090116.175% |
| ONE Bio Corp. | 27.49 Million USD | -14495.973% |
| Accustem Sciences Inc. | 1.07 Million USD | -371762.118% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -5083.979% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -189647.048% |
| Q BioMed Inc. | 8.13 Million USD | -49246.011% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -4739.068% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -77887.829% |
| Biomind Labs Inc. | 1.49 Million USD | -267699.871% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -3280.396% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -44283.929% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -21707.262% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -279793.309% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -2824264.686% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -69746.955% |
| GB Sciences, Inc. | 5.41 Million USD | -73979.165% |
| Alpha Cognition Inc. | 7.16 Million USD | -55914.063% |
| HST Global, Inc. | 593.59 Thousand USD | -675999.786% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -318618.497% |
| Halberd Corporation | 728.71 Thousand USD | -550630.94% |
| Enzolytics Inc. | 365.26 Million USD | -998.719% |
| Agentix Corp. | 2.51 Million USD | -159756.327% |
| Resverlogix Corp. | 67.39 Million USD | -5854.776% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -478393.845% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | -801.96% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -234047.083% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -16117.88% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -33616.264% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -109397.992% |
| AVAX Technologies, Inc. | 3.99 Million USD | -100389.165% |
| Zenith Capital Corp. | 27.56 Thousand USD | -14557123.693% |
| Genscript Biotech Corporation | 1.32 Billion USD | -202.69% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -1681531.567% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -107370.598% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -589365.42% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -147901.929% |
| Kadimastem Ltd | 3.5 Million USD | -114405.943% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -5996225.957% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -863530.221% |
| LadRx Corporation | 2.2 Million USD | -182278.093% |
| Cell Source, Inc. | 15.8 Million USD | -25289.724% |
| Regen BioPharma, Inc. | 5.45 Million USD | -73435.423% |
| NovAccess Global Inc. | 7.86 Million USD | -50954.8% |
| Affymax, Inc. | 8.87 Million USD | -45140.458% |
| Itoco Inc. | 1.65 Million USD | -242665.543% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -195520.465% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -66246.189% |
| Mobile Lads Corp. | 1.31 Million USD | -305441.695% |
| CytoDyn Inc. | 127.89 Million USD | -3037.974% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -9601280.416% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -256114.245% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -36234.776% |
| SYBLEU INC | 681.41 Thousand USD | -588864.549% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -65670.952% |
| International Stem Cell Corporation | 5.27 Million USD | -75952.321% |
| Bioxytran, Inc. | 3.24 Million USD | -123404.57% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -641194.868% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -86821.645% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -9689.445% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -17925.066% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -198048.848% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -73161.793% |
| Neutra Corp. | 973.52 Thousand USD | -412140.519% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -13731.746% |
| PureTech Health plc | 125.58 Million USD | -3095.72% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -106717.873% |
| IXICO plc | 1.9 Million USD | -211092.859% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -19449.325% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -3784.171% |
| CSL Limited | 18.62 Billion USD | 78.448% |
| Cellectis S.A. | 249.36 Million USD | -1509.372% |